Item 1.01. Entry
into a Material Definitive Agreement.
On May
23, 2008, SciClone Pharmaceuticals International Limited, a 100% subsidiary of
SciClone
Pharmaceuticals, Inc. (collectively, the "Company"), executed a Manufacturing
Supply Agreement, dated as of December 31, 2006, with Lonza Sales Limited (the
“Agreement”), pursuant to which the Company will purchase active pharmaceutical
ingredient for its lead product Zadaxin® (thymalfasin). The initial term
of the Agreement is for three years (through December 31, 2009) with a right of
the Company to extend for an additional two-year period.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Dated:
May 30, 2008
|
SCICLONE
PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/
Friedhelm Blobel
|
|
|
Friedhelm
Blobel
|
||
|
President
and Chief Executive Officer
|
||